+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032- Product Image
Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032- Product Image
Sale

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010903
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilar Monoclonal Antibodies Market is projected to reach USD 9.91 Billion in 2026. It is expected to continue growing at a CAGR of 11.49%, reaching USD 19.05 Billion by 2032.

Biosimilar monoclonal antibodies are moving from a cost-containment option to a core pillar of biologic therapy access across oncology, immunology, ophthalmology, and inflammatory diseases. These products are approved through rigorous comparability pathways requiring analytical, nonclinical, pharmacokinetic, immunogenicity, and clinical evidence showing no clinically meaningful differences from reference biologics in safety, purity, and potency.

The market is shaped by patent expirations for high-revenue biologics, increasing payer pressure, and expanding physician confidence as real-world evidence accumulates. Regulatory precedents from the FDA, EMA, WHO, and national agencies have strengthened trust in biosimilar monoclonal antibodies, while hospital formularies and specialty pharmacy channels are accelerating adoption where procurement systems reward value-based competition.

Transformative Shifts Reshaping Biosimilar Monoclonal Antibodies

The competitive landscape is undergoing a structural shift as biosimilar monoclonal antibodies expand beyond early infliximab, trastuzumab, rituximab, and bevacizumab categories into broader immunology and ophthalmology opportunities. The U.S. entry of multiple adalimumab biosimilars in 2023 marked a pivotal access milestone, reinforcing that payer contracting, interchangeability decisions, formulary placement, and channel strategy can be as important as regulatory approval.

Manufacturers are responding with more efficient cell-line development, advanced analytics, high-concentration formulations, citrate-free presentations, and device differentiation. At the same time, health systems are tightening evidence expectations around switching, extrapolation of indications, immunogenicity, pharmacovigilance, and supply reliability, making manufacturing quality and post-market data central competitive differentiators.

Cumulative Impact of Artificial Intelligence on Biosimilar Development

Artificial intelligence is cumulatively improving the biosimilar monoclonal antibody value chain by accelerating candidate characterization, predicting critical quality attributes, optimizing cell-culture parameters, and supporting comparability assessments. Machine learning models are increasingly used to interpret high-dimensional analytical data from glycosylation, charge variants, aggregation, binding affinity, and potency assays, helping teams identify variability earlier in development.

AI also supports regulatory intelligence, pharmacovigilance signal detection, literature surveillance, demand planning, and market access strategy. However, adoption remains bounded by validation, data integrity, model explainability, cybersecurity, and regulatory documentation requirements. The most credible near-term impact is not replacing biosimilar evidence generation, but reducing development risk, improving manufacturing consistency, and strengthening post-launch monitoring.

Key Regional Insights Across Global Biosimilar Monoclonal Antibody Markets

Asia-Pacific is emerging as a strategic biosimilar monoclonal antibodies hub, supported by biologics manufacturing capacity in China, India, South Korea, and Japan, along with rising demand for affordable oncology, autoimmune, and ophthalmology therapies. Regulatory reforms across the region, including biosimilar guidelines aligned with international comparability principles, are improving confidence while local production policies help address affordability and supply continuity.

North America remains highly influenced by payer contracting, FDA biosimilar and interchangeable designations, reimbursement design, and specialty pharmacy dynamics, with the United States driving commercial complexity and Canada emphasizing provincial switching policies. Latin America is advancing through procurement-led access models, reliance pathways, and regulatory convergence, with Brazil and Mexico playing important roles in public health purchasing and biosimilar policy development.

Europe remains the most mature adoption environment, supported by EMA experience, national tendering systems, physician familiarity with biosimilar switching, and extensive real-world evidence in immunology and oncology. The Middle East, especially GCC markets, is expanding biologics access through public-sector investment, hospital modernization, and national health transformation programs, while Africa shows long-term potential where cold-chain infrastructure, pricing, local regulatory capacity, and procurement financing continue to shape uptake.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO Markets

ASEAN markets are prioritizing affordability, regulatory capacity building, and local manufacturing partnerships as demand rises for oncology and immunology biologics. Countries in the region are increasingly using national reimbursement lists, hospital tenders, and technology transfer collaborations to improve access while maintaining pharmacovigilance requirements for complex biologics.

The GCC is using centralized purchasing, hospital modernization, and national health transformation programs to expand biosimilar access, particularly in Saudi Arabia and the United Arab Emirates. The European Union remains the benchmark for biosimilar policy maturity, with centralized EMA evaluation, national substitution or switching frameworks, and country-level tendering driving competition and physician acceptance.

BRICS economies are strategically important because China, India, Brazil, and Russia combine large patient populations with domestic biologics ambitions, while South Africa’s access priorities highlight the need for affordability and reliable supply. G7 markets offer strong regulatory predictability and reimbursement sophistication, and NATO members in Europe and North America are increasingly focused on medicine supply resilience, biologic affordability, and secure pharmaceutical manufacturing networks.

Key Country Insights in Major Biosimilar Monoclonal Antibody Markets

The United States is a major commercial opportunity shaped by FDA approvals, interchangeable biosimilar designations, reimbursement design, pharmacy benefit management, and provider-administered buy-and-bill economics. Canada continues to promote biosimilar use through provincial reimbursement and switching policies, while Mexico and Brazil use public procurement, regulatory modernization, and institutional purchasing to broaden biologic access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established biosimilar prescribing experience, although tendering, physician autonomy, substitution policy, and payer incentives vary by country. Russia has emphasized domestic biologics production and import substitution policies, while China and India combine large treatment-naïve populations with expanding biosimilar manufacturing capacity, improving access to monoclonal antibody therapies across oncology and inflammatory diseases.

Japan maintains stringent regulatory standards and a cautious but evidence-based adoption environment, while South Korea is recognized as a major global biosimilar manufacturing base supported by advanced biologics infrastructure and regulatory experience. Australia supports uptake through reimbursement policy, reference pricing mechanisms, and clinician education, making it an important developed Asia-Pacific market for evidence-based biosimilar adoption.

Actionable Recommendations for Biosimilar Monoclonal Antibody Leaders

Industry leaders should prioritize portfolios aligned with high-value biologic patent expirations, clear differentiation in formulation or delivery, and strong supply reliability. Commercial success requires early payer engagement, robust health economic evidence, switching education, transparent immunogenicity communication, and pharmacovigilance programs that build confidence among prescribers, pharmacists, and patients.

Organizations should invest in advanced analytics, quality-by-design manufacturing, and real-world evidence platforms to demonstrate consistency beyond approval. Partnerships with hospitals, specialty pharmacies, government procurement agencies, and local manufacturers can improve market entry, particularly in price-sensitive regions where tender performance, cold-chain readiness, and access commitments determine scale.

Research Methodology for Evidence-Based Market Assessment

This executive summary is developed using a structured secondary research approach grounded in publicly available regulatory, clinical, policy, and market-access evidence. Core references include biosimilar guidance and approval databases from the FDA, EMA, WHO, national regulatory authorities, public procurement frameworks, peer-reviewed literature, clinical trial registries, pharmacovigilance resources, and recognized healthcare policy sources.

The methodology emphasizes triangulation across regulatory approvals, patent and exclusivity events, payer policy trends, therapeutic adoption patterns, switching guidance, and manufacturing capabilities. Insights were assessed for relevance to monoclonal antibody biosimilars, with preference for verifiable evidence over promotional claims and a focus on commercially actionable trends without relying on market sizing, market share, or forecasting assumptions.

Conclusion: Biosimilar Monoclonal Antibodies Enter a Scaled Access Era

Biosimilar monoclonal antibodies are becoming essential to sustainable biologic care as health systems seek to reduce costs while preserving clinical outcomes. The market is no longer defined only by approval counts; it is increasingly driven by interchangeability, contracting strategy, physician confidence, real-world evidence, pharmacovigilance, and manufacturing excellence.

Organizations that combine scientific rigor with agile market access execution will be best positioned to strengthen adoption. As AI-enabled analytics, regulatory maturity, and global procurement reforms advance, biosimilar monoclonal antibodies are expected to play a larger role in expanding patient access to high-value biologic therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Biosimilar Monoclonal Antibodies Market, by Antibody Class
7.1. Introduction
7.2. Chimeric Monoclonal Antibodies
7.3. Humanized Monoclonal Antibodies
8. Biosimilar Monoclonal Antibodies Market, by Molecule Class
8.1. Introduction
8.2. Adalimumab
8.3. Infliximab
8.4. Rituximab
8.5. Trastuzumab
8.6. Bevacizumab
8.7. Ranibizumab
9. Biosimilar Monoclonal Antibodies Market, by Dosage Form
9.1. Introduction
9.2. Liquid Solution
9.3. Lyophilized Powder
9.4. Prefilled Syringe
10. Biosimilar Monoclonal Antibodies Market, by Treatment Type
10.1. Introduction
10.2. Monotherapy
10.3. Combination Therapy
11. Biosimilar Monoclonal Antibodies Market, by Therapeutic Area
11.1. Introduction
11.2. Immunology
11.3. Oncology
11.4. Ophthalmology
11.5. Rheumatology
11.6. Autoimmune & Inflammatory Diseases
12. Biosimilar Monoclonal Antibodies Market, by End User
12.1. Introduction
12.2. Specialty Clinics
12.3. Hospitals
12.4. Home Healthcare
13. Biosimilar Monoclonal Antibodies Market, by Region
13.1. North America
13.2. Europe
13.3. Asia-Pacific
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Biosimilar Monoclonal Antibodies Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Biosimilar Monoclonal Antibodies Market, by Country
15.1. United States
15.2. China
15.3. Canada
15.4. Germany
15.5. Brazil
15.6. Mexico
15.7. Japan
15.8. India
15.9. United Kingdom
15.10. France
15.11. Italy
15.12. Australia
15.13. South Korea
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Alvotech hf
17.2. Amgen Inc.
17.3. Aurobindo Pharma Ltd.
17.4. Bio-Thera Solutions, Ltd.
17.5. Biocon Ltd.
17.6. Boehringer Ingelheim International GmbH
17.7. Celltrion, Inc.
17.8. Coherus BioSciences, Inc.
17.9. Dr. Reddy's Laboratories Ltd.
17.10. Formycon AG
17.11. Fresenius Kabi AG
17.12. Intas Pharmaceuticals Ltd.
17.13. Lupin Ltd.
17.14. Mabwell Bioscience
17.15. Merck KGaA
17.16. Pfizer Inc.
17.17. Polpharma Biologics Group
17.18. Qilu Pharmaceutical Co., Ltd.
17.19. Reliance Life Sciences
17.20. Samsung Bioepis Co., Ltd.
17.21. Sandoz International GmbH
17.22. Shanghai Henlius Biotech, Inc.
17.23. Stada Arzneimittel AG
List of Figures
FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ADALIMUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ADALIMUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ADALIMUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL INFLIXIMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL INFLIXIMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL INFLIXIMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL RITUXIMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL RITUXIMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL RITUXIMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL TRASTUZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL TRASTUZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL TRASTUZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL RANIBIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL RANIBIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL RANIBIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL LIQUID SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL LIQUID SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL LIQUID SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL RHEUMATOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL RHEUMATOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL RHEUMATOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 75. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 76. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 77. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 78. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 80. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 82. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 83. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 84. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 85. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 86. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 103. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 104. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 105. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 106. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 107. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 118. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 119. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 120. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 121. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 122. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 125. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 126. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 127. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 128. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 129. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 139. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 140. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 141. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 142. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 143. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 146. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 147. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 148. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 149. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 150. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 153. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 154. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 155. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 156. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 157. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 160. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 161. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 162. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 163. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 164. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 165. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 167. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 168. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 169. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 170. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 171. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 172. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 174. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 175. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 176. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 177. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 178. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 179. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 181. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 182. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 183. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 184. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 185. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 186. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 188. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 189. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 190. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 191. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 192. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 193. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 195. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 196. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 197. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 198. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 199. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 200. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 203. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 204. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 205. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 206. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 207. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 209. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 210. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 211. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 212. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 214. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 217. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 218. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 219. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 220. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 221. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 224. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 225. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 226. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 227. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 228. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 231. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 232. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 233. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 234. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 235. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 238. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 239. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 242. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 245. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 246. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 247. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 248. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 249. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 252. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 253. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 254. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 255. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 256. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2017-2032 (USD MILLION)
TABLE 259. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2017-2032 (USD MILLION)
TABLE 260. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 261. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 262. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 263. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 265. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Alvotech hf
  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • Bio-Thera Solutions, Ltd.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Formycon AG
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Mabwell Bioscience
  • Merck KGaA
  • Pfizer Inc.
  • Polpharma Biologics Group
  • Qilu Pharmaceutical Co., Ltd.
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Shanghai Henlius Biotech, Inc.
  • Stada Arzneimittel AG

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.91 Billion
Forecasted Market Value ( USD ) by 2032 $ 19.05 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Oncology Biosimilars Market - Global Forecast 2026-2032 - Product Image

Oncology Biosimilars Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Monoclonal Antibody Therapeutics Market - Global Forecast 2026-2032 - Product Image

Monoclonal Antibody Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Biosimilar Monoclonal Antibodies Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Cancer Monoclonal Antibodies Market Size, Share, Trends and Forecast by Antibody Type, Medication Type, Application, End User, and Region, 2026-2034 - Product Image

Cancer Monoclonal Antibodies Market Size, Share, Trends and Forecast by Antibody Type, Medication Type, Application, End User, and Region, 2026-2034

  • Report
  • 136 Pages
  • Global
From
Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2026-2034 - Product Image

Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2026-2034

  • Report
  • 146 Pages
  • Global
From

About the Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies (mAbs) are biotechnological products that are similar to existing monoclonal antibodies (mAbs) that are already approved for use in humans. Biosimilar mAbs are developed using recombinant DNA technology and are designed to have the same structure and function as the original mAbs. Biosimilar mAbs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. They are also used in research and development of new treatments. The biosimilar mAbs market is growing rapidly due to the increasing demand for mAbs in the treatment of various diseases. The market is expected to continue to grow as more mAbs are developed and approved for use in humans. Additionally, the increasing demand for mAbs in research and development is expected to drive the growth of the market. Some companies in the biosimilar mAbs market include Amgen, Biogen, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.